Ex­clu­sive: Fol­low­ing a se­vere set­back, Bridge­Bio brings out the bud­get axe to chop staff but keeps qui­et on the num­bers

Three months af­ter Bridge­Bio’s TTR amy­loi­do­sis can­di­date suf­fered a ma­jor — and ac­cord­ing to CEO Neil Ku­mar, “baf­fling” — Phase III fail that wiped out $4 bil­lion …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER